TNFRSF8 and Hodgkins lymphoma: As a first proof-of-concept study, an eSrtA-conjugated version of the CD30-specific ADC brentuximab vedotin (Adcetris), currently marketed for the treatment of Hodgkin's lymphoma, was produced.